ZENITH trial
Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data
Roche; Alnylam; zilebesiran; hypertension; RNAi therapeutics; KARDIA-3; Phase II trial; Phase III trial; cardiovascular outcomes; ZENITH trial